title: Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states.
abstract: Telomerase activity was measured in surgically resected tissues of 20 human pancreatic ductal carcinomas, 12 adenomas, 5 pancreatitis tissues, 14 normal pancreatic ducts, and 13 normal pancreatic tissues (primarily made up of acinar cells) using a PCR-based telomerase assay. Relative telomerase activity was expressed as the equivalent telomerase intensity of the number of cells of a human pancreatic cancer cell line, MIA PaCa-2, per microgram of protein in the tissue samples. The median value (25th percentile, 75th percentile) of relative telomerase activity in pancreatic carcinomas was 13.2 (3.58, 244), which was significantly higher relative to normal tissues, normal ducts, pancreatitis tissues, and adenomas (P < 0.0001). When the cutoff value of relative telomerase activity was set at 1.00 and 3.00, the positivity rates of telomerase activity in pancreatic ductal carcinomas were 100 and 80%, respectively. Some of the adenoma samples displayed a weak telomerase ladder. However, when semiquantitatively analyzed, the relative telomerase activity of all adenoma tissues was less than 1.00 equivalent cells per microgram protein of the tissues, which was equivalent to the values encountered in normal ducts. Thus, our results indicate that reactivation of telomerase may occur at a late stage of pancreatic ductal carcinogenesis. Therefore, telomerase may be a specific marker for distinguishing pancreatic cancer from pancreatitis and adenomas.
authors.affiliation: Departments of Surgery 1, Clinical Chemistry and Laboratory Medicine, and Pathology 2, Kyushu University Faculty of Medicine, Fukuoka 812-82, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Suehara
authors.forename: K
authors.initials: K
authors.lastname: Mizumoto
authors.forename: T
authors.initials: T
authors.lastname: Muta
authors.forename: Y
authors.initials: Y
authors.lastname: Tominaga
authors.forename: H
authors.initials: H
authors.lastname: Shimura
authors.forename: S
authors.initials: S
authors.lastname: Kitajima
authors.forename: N
authors.initials: N
authors.lastname: Hamasaki
authors.forename: M
authors.initials: M
authors.lastname: Tsuneyoshi
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000201:enzymology* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010179:Pancreas / Q000166:cytology / Q000201:enzymology* / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D010195:Pancreatitis / Q000201:enzymology* / Q000473:pathology; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019098:Telomerase / Q000032:analysis* / Q000235:genetics; D014407:Tumor Cells, Cultured
chemical_list: D019098:Telomerase